Meeting NewsVideo

VIDEO: Advances in CAR T cells offer significant potential for patients with leukemia

SAN DIEGO — The use of a fourth-generation CAR T-cell therapy demonstrated high remission rates and appeared well tolerated in children and adults with acute B-cell lymphoblastic leukemia, according to Joshua Brody, MD, director of the Lymphoma Immunotherapy Program, at the Icahn School of Medicine at Mount Sinai Hospital in New York.

In this video, Brody discusses the results of two studies presented at the ASH Annual Meeting and Exposition that demonstrated that CAR T cells appear effective and safe in the treatment of ALL.

“We have chimeric antigen receptor T-cell studies [that] are adding to the already impressive collection of data that we have,” Brody told HemOnc Today.

Lung-Ji Chang, PhD, from the University of Florida Health, and colleagues conducted a phase 1/ phase 2 study of 102 eligible children and adults with B-ALL to assess the safety and efficacy of a fourth-generation CAR T cell.

More than 90% of patients (n = 69) with a bone marrow blast count less than 50% achieved a complete response after treatment, and 75.8% of patients (n = 33) with a blast count greater than or equal to 50% achieved CR.

In addition, Brody highlights the results of a study that Rebecca A. Gardner, MD, assistant professor at Seattle Children’s Hospital, and colleagues presented that showed early intervention with pre-emptive tocilizumab (Actemra, Genentech) and dexamethasone decreased rates of severe cytokine release syndrome by 50%.

Brody notes that although studies assessing the efficacy of CAR T cells have been impressive, there has been a growing concern surrounding toxicities.

“[This] important study … shows that we can use prophylactic therapy to help to avoid severe cytokine release syndromes … [which is] one of the primary causes of morbidity and mortality with CAR T cells,” Brody said. “If we can get that same great efficacy with less toxicity, this would be a big deal for our patients,” Brody said.

Reference: Gardner R, et al. Abstract 586. Presented at: ASH Annual Meeting and Exposition; Dec. 3-6, 2016; San Diego.

Chang LJ, et al. Abstract 587. Presented at: ASH Annual Meeting and Exposition; Dec. 3-6, 2016; San Diego.

Disclosure: Brody reports no relevant financial disclosures.

SAN DIEGO — The use of a fourth-generation CAR T-cell therapy demonstrated high remission rates and appeared well tolerated in children and adults with acute B-cell lymphoblastic leukemia, according to Joshua Brody, MD, director of the Lymphoma Immunotherapy Program, at the Icahn School of Medicine at Mount Sinai Hospital in New York.

In this video, Brody discusses the results of two studies presented at the ASH Annual Meeting and Exposition that demonstrated that CAR T cells appear effective and safe in the treatment of ALL.

“We have chimeric antigen receptor T-cell studies [that] are adding to the already impressive collection of data that we have,” Brody told HemOnc Today.

Lung-Ji Chang, PhD, from the University of Florida Health, and colleagues conducted a phase 1/ phase 2 study of 102 eligible children and adults with B-ALL to assess the safety and efficacy of a fourth-generation CAR T cell.

More than 90% of patients (n = 69) with a bone marrow blast count less than 50% achieved a complete response after treatment, and 75.8% of patients (n = 33) with a blast count greater than or equal to 50% achieved CR.

In addition, Brody highlights the results of a study that Rebecca A. Gardner, MD, assistant professor at Seattle Children’s Hospital, and colleagues presented that showed early intervention with pre-emptive tocilizumab (Actemra, Genentech) and dexamethasone decreased rates of severe cytokine release syndrome by 50%.

Brody notes that although studies assessing the efficacy of CAR T cells have been impressive, there has been a growing concern surrounding toxicities.

“[This] important study … shows that we can use prophylactic therapy to help to avoid severe cytokine release syndromes … [which is] one of the primary causes of morbidity and mortality with CAR T cells,” Brody said. “If we can get that same great efficacy with less toxicity, this would be a big deal for our patients,” Brody said.

Reference: Gardner R, et al. Abstract 586. Presented at: ASH Annual Meeting and Exposition; Dec. 3-6, 2016; San Diego.

Chang LJ, et al. Abstract 587. Presented at: ASH Annual Meeting and Exposition; Dec. 3-6, 2016; San Diego.

Disclosure: Brody reports no relevant financial disclosures.

    See more from Discoveries from ASH: Leukemia